A major U.S. drug maker is developing a test to combat infection in patients receiving hip and knee replacements, according to a Fox News report.
Abbott Diagnostics Group, a unit of Abbott Laboratories, is partnering with the privately held Genetics Laboratory, which specializes in orthopedics, to develop the test. Based on Abbott's PLEX-ID system for identifying microbes, the test aims to help physicians detect infections in the body's joints long before the patient displays physical symptoms.
"Orthopedics is one of the leading opportunities for this technology because of what it's able to do for patients who have orthopedic infections, which are difficult to diagnose by conventional methods," said Dave Ecker, divisional vice president at Abbott Molecular.
Related Articles on Devices and Implants:
TranS1 Reports 32% Drop in 4Q Revenue
American Joint Replacement Registry Now Includes 19k Procedures
Orthopedic Instrumentation Market to Reach $56B by 2017
Abbott Diagnostics Group, a unit of Abbott Laboratories, is partnering with the privately held Genetics Laboratory, which specializes in orthopedics, to develop the test. Based on Abbott's PLEX-ID system for identifying microbes, the test aims to help physicians detect infections in the body's joints long before the patient displays physical symptoms.
"Orthopedics is one of the leading opportunities for this technology because of what it's able to do for patients who have orthopedic infections, which are difficult to diagnose by conventional methods," said Dave Ecker, divisional vice president at Abbott Molecular.
Related Articles on Devices and Implants:
TranS1 Reports 32% Drop in 4Q Revenue
American Joint Replacement Registry Now Includes 19k Procedures
Orthopedic Instrumentation Market to Reach $56B by 2017